NEW YORK – AnchorDx, a Guangzhou, China-based cancer diagnostics developer, said on Monday that it has completed a $40 million Series C financing round.
OrbiMed and WuXi Huiying Investment jointly led the financing round. AnchorDx plans to use the funds to accelerate the registration and commercialization of its next-generation sequencing-based products for cancer, multi-cancer, and pan-cancer screening and early detection. The company said it also plans to develop its technology for other major disease areas.